Altimmune, Inc. - 8-K Filing

Altimmune reports Q3 2026 net loss of $31.6 million and maintains $480 million in cash and investments. (Items: 2.02 Results of Operations and Financial ConditionOn November 12, 2026, Altimmune, Inc, 9.01 Financial Statements and Exhibits(d) ExhibitsNo)

SEC EDGAR · November 12, 2026, 12:33 UTC

Tickers: $ALT

Read the full article at SEC EDGAR

Part of the story Altimmune, Inc. - 8-K Filing (3 articles)

More Regulatory news

Ondas Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:24 UTC
CLARIVATE PLC - 8-K Filing SEC EDGAR · November 12, 2026, 13:24 UTC
CorMedix Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:21 UTC
Corvex, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:21 UTC
Leatt Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:20 UTC
Leatt Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:18 UTC
FILANA THERAPEUTICS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:18 UTC
RUM Group Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:17 UTC
Theriva Biologics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SeaStar Medical Holding Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC